Drug Profile


Alternative Names: VX745

Latest Information Update: 10 Jan 2017

Price : $50

At a glance

  • Originator Vertex Pharmaceuticals
  • Developer EIP Pharma; Vertex Pharmaceuticals
  • Class Anti-inflammatories; Small molecules
  • Mechanism of Action P38 mitogen-activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Alzheimer's disease
  • Discontinued Asthma; Crohn's disease; Rheumatoid arthritis; Stroke

Most Recent Events

  • 16 Nov 2016 EIP Pharma completes a phase II trial in Alzheimer's disease (In the elderly) in USA (NCT02423200)
  • 16 Nov 2016 EIP Pharma completes a phase II trial in Alzheimer's disease in the Netherlands (NCT02423122)
  • 28 Sep 2016 EIP Pharma has patent protection for neflamapimod in USA, Europe and Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top